Saroja PIK3CA-mutated hormone receptor–positive gorenganbubuk

Added on April 2, 2025

Address: 2038 Jewell Road

Business Email: frenzinaomi@gmail.com

Contact: +916127027194

Website: https://www.twosapp.com/67ec4bcdc71d5f30555edcab

from the phase 3 DESTINY-Breast06 trial (NCT04494425), in which treatment with T-DXd generated a 36% reduction in the risk of disease progression or death compared with chemotherapy (HR, 0.64; 95% CI, 0.54-0.76; P < .0001) in the overall population of patients with chemotherapy-naive HER2-low -ultralow metastatic breast cancer.1,2 The median progression-free survival (PFS) was 13.2 months (95% CI, 12.0-15.2) with T-DXd vs 8.1 months (95% CI, 7.0-9.0) with chemotherapy. Additionally, the confirmed overall response rate (ORR) was 62.6% with T-DXd compared with 34.4% with chemotherapy.

“Endocrine therapy is typically used in the initial treatment of hormone receptor–positive metastatic breast cancer, and following progression, subsequent chemotherapy is associated with poor outcomes," Aditya Bardia, MD, MPH, program director of Breast Oncology and director of Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center, as well as the lead study author of the DESTINY-Breast06 trial, stated in a news release.1 "With a median PFS exceeding 1 year and [an ORR of 62.6%], T-DXd offers a potential new standard of care for patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer following endocrine therapy.”

The multicenter, open-label DESTINY-Breast06 trial enrolled patients with hormone receptor–positive metastatic breast cancer with low HER2 expression (defined as IHC 1+ or 2+ and negative ISH results) or ultralow HER2 expression (defined as IHC 0 with no membrane staining) who had previously received at least 1 line of endocrine-based therapy and had no history of chemotherapy for metastatic breast cancer.2 Patients were randomly assigned 1:1 to receive T-DXd or physician's choice of chemotherapy. PFS among patients with HER2-loe disease served as the primary end point. Secondary end points included PFS among all randomly assigned patients, overall survival (OS), and safety.

Additional findings from DESTINY-Breast06, which were presented at the 2024 ASCO Annual Meeting and published in The New England Journal of Medicine, showed that among the patients with HER2-low disease (n = 713), the median PFS was 13.2 months (95% CI, 11.4-15.2) with T-DXd vs 8.1 months (95% CI, 7.0-9.0) with chemotherapy (HR, 0.62; 95% CI, 0.52-0.75; P < .001).

Saroja PIK3CA-mutated hormone receptor–positive gorenganbubuk

Trusted Tech Waste Recycling – Iris Recycling

Laptop Rental in Dubai, UAE - Hire LED Touch Screens, TV, Video Wall

Quick & Secure PDF Splitter Software for Easy Document Management

Avast Help Australia

KYP Center Ekma Saran Bihar

MSG Converter – Never Struggle with Email Files Again!

Saroja PIK3CA-mutated hormone receptor–positive gorenganbubuk

Sign In

Register

Reset Password